Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Dfe Pharma GmbH & Co. Kg has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution is currently managed by 1 distinct examiner and is located within 1 distinct art unit. This concentration indicates that the company's active patent applications are being reviewed by a single individual in a specific technical group. In the pharmaceutical industry, this level of focus can help in maintaining a consistent approach to the disclosure and defense of pharmaceutical compositions and methods.
SEAN JAMES STEINKE is the busiest examiner for the portfolio, with 1 busiest examiner pending office action. This action represents the total of 1 pending office action for the company. The alignment of 1 distinct examiner and 1 distinct art unit suggests a direct and singular channel for the current pharmaceutical-related prosecution. This allows the practitioner to focus on a single set of examiner preferences and art unit guidelines. By concentrating on this one point of contact, the applicant can more efficiently address the pending office action and work toward a resolution without the complexity of managing multiple examiners or different technical departments.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEINKE, SEAN JAMES | 1 | 12.5% | +42.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18431282 | METHOD FOR PREPARING CO-PROCESSED EXCIPIENT GRANULES | STEINKE, SEAN JAMES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18431282 | METHOD FOR PREPARING CO-PROCESSED EXCIPIENT GRANULES | STEINKE, SEAN JAMES | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18431282 | METHOD FOR PREPARING CO-PROCESSED EXCIPIENT GRANULES | STEINKE, SEAN JAMES | 1619 | §103§112 | Non-Final OA | — | Pending | Feb 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDfe Pharma GmbH & Co. Kg has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sean James Steinke has the most, with 1 of Dfe Pharma GmbH & Co. Kg's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.